Publicerade rapporter och nyheter

DateTimeSubjectDocuments
9/19/201712:45 PMOncology Venture: Rekrytering pågår till LiPlaCis fas-2-studie med DRP-screenade bröstcancerpatienter: relevanta kliniska effekter ses hos 3 av 5 behandlade patienterLäs som pdf - Oncology Venture
9/19/201712:45 PMOncology Venture: LiPlaCis Phase 2 Recruitment Ongoing in DRP Screened Breast Cancer Patients: Relevant Clinical Benefits in 3 out of 5 Treated PatientsRead as pdf - Oncology Venture
8/25/20171:43 PMOncology Venture: Half-year Report 2017-01-01 - 2017-06-30Read Half-year Report. - Oncology Venture
8/25/20171:42 PMOncology Venture: Halvårsrapport 2017-01-01 - 2017-06-30Läs halvårsrapport. - Oncology Venture
8/23/201712:03 PMOncology Venture: Pipeline updatesee pressrelease - Oncology Venture
8/23/201712:03 PMOncology Venture: Uppdatering av Oncology Ventures pipelineSe pressmeddelandet som PDF - Oncology Venture
8/1/20172:10 PMOncology Venture: Successful DRP™ prediction of patients treated with 2X-121, the PARP inhibitor recently licensed from EisaiSee press release - Oncology Venture
8/1/20172:10 PMOncology Venture: Framgångsrik DRP™-förutsägelse av patienter behandlade med 2X-121, den nyligen licensierade PARP-hämmaren från EisaiSe pressmeddelade - Oncology Venture
7/19/20179:00 AMOncology Venture: OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical companyRead as pdf - Oncology Venture
7/7/20172:30 PMOncology Venture: Oncology Venture och Eisai ingår exklusivt globalt licensavtal för den kliniska onkologiska läkemedelskandidaten PARP Inhibitor E7449/2X-121Se pressmeddelande - Oncology Venture
7/7/20172:30 PMOncology Venture: Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121See press release - Oncology Venture
7/6/20174:52 PMOncology Venture: Fas 2-studien med LiPlaCis® tillåts nu tidigare patientinkludering samt inkludering av patienter med svårbehandlad bröstcancerSe pressmeddelande - Oncology Venture
7/6/20174:52 PMOncology Venture: LiPlaCis® Phase 2 now allowed for earlier inclusion & inclusion of patients with hard to treat breast cancerSee press release - Oncology Venture
6/27/201711:00 AMOncology Venture: Successful prediction of Cancer response to LiPlaCis® in Breast cancer and other tumors by OV's DRP™ - strong support for randomized Phase 2See press release - Oncology Venture
6/27/201711:00 AMOncology Venture: Framgångsrik förutsägelse av respons med LiPlaCis® i bröstcancer och andra tumörtyper med OVs DRP - starkt stöd för randomiserad fas 2 i bröstcancerSe pressmeddelande - Oncology Venture
1  2  3  4  5  6  7  8  

  • Mäster Samuelsgatan 42
  • 111 57 Stockholm
  • Telefon: 08 - 511 68 000
  • info(snabel-a)aktietorget(punkt)se